Overview: Therapeutic Biomarkers in Cancer, Sherry X. Yang and Janet E. DanceyStatistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in Cancer, Lisa M. McShane, Edward L. Korn and Boris FreidlinRole of Biomarkers in Clinical Development of New Cancer Therapies, Helen X. ChenHER2 as a Prognostic and Predictive Biomarker in Cancer, Suparna Wedam and Stan LipkowitzHormone Receptors and Endocrine Therapy in Breast Cancer, Chia C. Portera and Sherry X. YangPredictive Biomarkers for Epidermal Growth Factor Receptor (EGFR) Agents in Non-Small Cell Lung Cancer, John Hilton, Penelope A. Bradbury, and Janet E. DanceyMarkers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer, Jose G. Monzon and Janet E. DanceyTargeting BCR-ABL for Molecular Therapy of Chronic Myelogenous Leukemia, Shamudheen Rafiyath, Guoqing Wei, and Delong LiuGastrointestinal Stromal Tumors (GISTs): From Molecular Pathogenesis to Therapy, Joaquina Baranda, Rashna Madan and Andrew K. GodwinPML/RARa Fusion Gene and Response to Retinoic Acid and Arsenic Trioxide Treatment, Alicja Gruszka and Myriam AlcalayDihydropyrimidine Dehydrogenase Deficiency and 5-Fluouracil Toxicity, Eva Gross and Andre B. P. van KuilenburgUGT1A1 Polymorphisms and Mutations Lead to Irinotecan-Induced Toxicity, Kellie Reece and William D. FiggThe 21-Gene Recurrence Score and Benefit of Chemotherapy in Estrogen Receptor-Positive Breast Cancer, Petra Rietchel and Joseph A. SparanoMammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients, Sonal J. Desai and Tianhong LiBRCA mutation and PARP Inhibitors, Marcie K. Weil, Shivaani Kummar, James H. Doroshow, and Alice P. ChenEML4-ALK Fusion Gene and Therapy with ALK-targeted Agents in Non-Small Cell Lung Cancer, Vimal Patel, MD and Biren SaraiyaBRAF-Targeted Therapy in Metastatic Melanoma, Noori Kim and April C. Deng